HC Wainwright restated their buy rating on shares of Genfit (NASDAQ:GNFT - Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $13.00 target price on the stock.
Genfit Trading Down 0.9 %
Shares of GNFT stock traded down $0.04 during trading hours on Friday, reaching $3.89. The company had a trading volume of 1,286 shares, compared to its average volume of 8,412. The stock's fifty day simple moving average is $3.75 and its 200 day simple moving average is $4.43. Genfit has a twelve month low of $3.35 and a twelve month high of $6.42. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74.
Genfit Company Profile
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Recommended Stories
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
